Literature DB >> 21951215

Differences in tissue expression of HBV markers in children with HBV-associated glomerulonephritis.

Xiaoyan Li1, Aiwen Huang, Pin Zhou, Xiqiang Dang, Shuanghong Mo, Zhuwen Yi, Qingnan He.   

Abstract

BACKGROUND/AIMS: Hepatitis B virus-associated glomerulonephritis (HBV-GN) is recognized as one of the major secondary nephropathies in HBV high-risk areas. To determine possible differences in the expression of HBV immune markers in tissues, we retrospectively examined HBV immune markers in the serum, renal tissues, and liver tissues in 132 HBV-GN children.
METHODS: All 132 patients had biopsy-proven HBV-GN including the presence of positive HBV antigens in the kidney. Serum-HBV immune markers were tested by an enzyme-linked immunosorbent assay. Renal and liver biopsies were done in 26 patients. All renal tissues were examined for HBV immune markers by immunofluorescence, and liver tissues were examined by immunohistochemistry.
RESULTS: Among the 132 patients, all showed varying degrees of kidney injury. Serum hepatitis B envelope antigen (HBeAg) was positive in 80 patients and negative in 52 patients. The positivity rate of Hepatitis B core antigen in renal tissue was statistically higher in serum HBeAg (-) than in serum HBeAg (+) patients (96.2% vs. 55.0%). Furthermore, there was no relationship between the presence of hepatitis B surface antigen and HBcAg in liver and renal tissue.
CONCLUSION: HBV markers are not consistently present in serum, renal tissues, and liver tissues in children with HBV-GN.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21951215     DOI: 10.3109/0886022X.2011.605979

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  1 in total

1.  Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.

Authors:  Li-Jing Sun; Jian-Ping Shan; Ruo-Lan Cui; Wei-Jie Yuan; Geng-Ru Jiang
Journal:  Int Urol Nephrol       Date:  2017-03-10       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.